Effectiveness and safety of Pingxiao capsule(平消胶囊)as adjuvant therapy in treatment of breast cancer:a systematic review and Meta-analysis

被引:0
|
作者
YANG Yuqing [1 ]
CHEN Yuhuan [1 ]
LI Chunxiao [2 ]
LING Xiao [2 ]
WANG Panpan [2 ]
GUO Jing [1 ]
ZHANG Yingying [1 ]
机构
[1] Henan University of Chinese Medicine
[2] Department of Pharmacy the First Affiliated Hospital of Henan University of Chinese Medicine Henan Province Engineering Research Center for Clinical Application,Evaluation and Transformation of Traditional Chinese Medicine Henan Provincial Key Laboratory f
关键词
D O I
10.19852/j.cnki.jtcm.20230713.001
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
摘要
OBJECTIVE: To systematically review the effectiveness and safety of Pingxiao capsule( 平 消 胶 囊) adjuvant chemotherapy in the treatment of breast cancer. METHODS: A total of 8 databases including the Cochrane Library, PubMed, EMBASE, Engineering Index, Chinese Biomedical Literature Database, Wanfang database, China National Knowledge Infrastructure Database, and China Science and Technology Journal Database were searched for the Randomized Controlled Trials(RCTs) of Pingxiao capsule combined with chemotherapy in the treatment of breast cancer published before June 2022. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias. R language was used for estimating risks of bias of included studies, data analysis, and plotting. RESULTS: A total of 15 RCTs involving 1272 patients were included in this study. Meta-analysis results indicated that compared with chemotherapy alone, Pingxiao capsule combined with chemotherapy could significantly improve breast cancer patients' objective response rate of breast cancer patients [rate ratio(RR) = 1.35, 95% confidence interval(CI)(1.12, 1.63), P = 0.0017], the disease control rate [RR=1.16, 95% CI(1.08, 1.25), P < 0.0001], the quality of life [RR =1.42, 95% CI(1.16, 1.74), P = 0.007], and the level of the immune cells [CD3+: standardized mean difference(SMD) =1.42, 95% CI(0.76, 2.09), P < 0.001; CD4+: SMD =1.18, 95% CI(0.70, 1.66), P < 0.001]. In addition, Pingxiao capsule combined with chemotherapy can also significantly reduce CD8+ level(P < 0.0001) and reduce the symptoms of decreased white blood cell count [SMD = 0.62, 95% CI(0.39, 0.85), P < 0.0001], and the occurrence of adverse reactions such as gastrointestinal adverse reactions and limb pain(P < 0.05). CONCLUSIONS: Pingxiao capsule can significantly improve the efficacy of chemotherapy, the quality of life and immune function of patients, and reduce the clinical side effects caused by chemotherapy. However, highquality randomized clinical trials with large samples are required for further verification of these results.
引用
收藏
页码:851 / 859
页数:9
相关论文
共 9 条
  • [1] 卡培他滨节拍化疗晚期乳腺癌效果的Meta分析
    陈学东
    张丰羽
    陈全
    贺志明
    [J]. 邵阳学院学报(自然科学版), 2021, 18 (05) : 32 - 38
  • [2] 平消胶囊含药血清联合紫杉醇对乳腺癌细胞的作用及机制研究
    朴明姬
    杜金柱
    王兴阳
    尹宝亮
    于王子
    许斌
    [J]. 广西医科大学学报, 2021, 38 (09) : 1717 - 1722
  • [3] 消肿散结汤联合平消胶囊对非哺乳期乳腺炎肿块期患者炎症因子及免疫因子的影响
    张玉杰
    韩兵
    黄浩然
    刘宇彪
    [J]. 医学综述, 2020, 26 (09) : 1856 - 1859
  • [4] 中药治疗对乳腺癌术后放化疗患者生活质量及毒副反应的影响
    贺新爱
    郜娜娜
    马馨
    李丽
    [J]. 肿瘤药学, 2016, 6 (05) : 349 - 355
  • [5] Sung Hyuna,Ferlay Jacques,Siegel Rebecca L.,Laversanne Mathieu,Soerjomataram Isabelle,Jemal Ahmedin,Bray Freddie.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA: A Cancer Journal for Clinicians,2021
  • [6] El-Masry Omar S,Brown Barry L,Dobson Pauline R M.AMPK Activation of Apoptotic Markers in Human Breast Cancer Cell Lines with Different p53 Backgrounds: MCF-7, MDA-MB-231 and T47D Cells[J].Asian Pacific journal of cancer prevention : APJCP,2019
  • [7] Agnieszka Kolak,Marzena Kamińska,Katarzyna Sygit,Agnieszka Budny,Dariusz Surdyka,Bożena Kukiełka-Budny,Franciszek Burdan.Primary and secondary prevention of breast cancer[J].Annals of Agricultural and Environmental Medicine,2017
  • [8] He Meilan,Tan Brandon,Vasan Karthik,Yuan Hongfeng,Cheng Fan,Ramos da Silva Suzane,Lu Chun,Gao Shou-Jiang.SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells[J].The Journal of pathology,2017
  • [9] Zhang Qing-yuan,Zhao Wen-hui,Lai Yu-juan[Effect on late-stage mammary cancer treated by endocrinotherapy or chemotherapy combined with pingxiao capsule][J].Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine,2005(12)